BR112023024942A2 - Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer - Google Patents
Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncerInfo
- Publication number
- BR112023024942A2 BR112023024942A2 BR112023024942A BR112023024942A BR112023024942A2 BR 112023024942 A2 BR112023024942 A2 BR 112023024942A2 BR 112023024942 A BR112023024942 A BR 112023024942A BR 112023024942 A BR112023024942 A BR 112023024942A BR 112023024942 A2 BR112023024942 A2 BR 112023024942A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- inhibitors
- combination
- atr
- parp
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 201000011510 cancer Diseases 0.000 title abstract 8
- 239000012661 PARP inhibitor Substances 0.000 title abstract 4
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 101100327354 Caenorhabditis elegans cdk-12 gene Proteins 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer. a presente invenção refere-se a métodos de tratamento de um câncer em um indivíduo utilizando um inibidor de atr e um inibidor de parp, em que o câncer foi previamente identificado como um câncer com perda de função de atm, brca2, rnase h2a, rnase h2b, cdk12 ou uma combinação dos mesmos, ou como um câncer alt+. também são descritos métodos para induzir a morte celular em uma célula cancerígena aberrante tendo uma perda de função de atm, brca2, rnase h2a, rnase h2b, cdk12, ou uma combinação dos mesmos, ou uma célula cancerígena alt+, colocando a célula em contato com uma quantidade eficaz de um inibidor de atr e um inibidor de parp.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211354P | 2021-06-16 | 2021-06-16 | |
| US202263336026P | 2022-04-28 | 2022-04-28 | |
| PCT/CA2022/050970 WO2022261777A1 (en) | 2021-06-16 | 2022-06-16 | Use of atr inhibitors in combination with parp inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024942A2 true BR112023024942A2 (pt) | 2024-02-15 |
Family
ID=84526073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024942A BR112023024942A2 (pt) | 2021-06-16 | 2022-06-16 | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4355334A1 (pt) |
| KR (1) | KR20240021884A (pt) |
| AU (1) | AU2022293208A1 (pt) |
| BR (1) | BR112023024942A2 (pt) |
| CA (1) | CA3222841A1 (pt) |
| IL (1) | IL309388A (pt) |
| WO (1) | WO2022261777A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202322807A (zh) | 2021-10-01 | 2023-06-16 | 美商辛瑟拉股份有限公司 | 吖丁啶及吡咯啶parp1抑制劑及其用途 |
| US11939329B2 (en) | 2022-01-21 | 2024-03-26 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| WO2023146960A1 (en) * | 2022-01-28 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| WO2023193114A1 (en) * | 2022-04-07 | 2023-10-12 | Repare Therapeutics Inc. | Methods of using atr inhibitors |
| TW202400596A (zh) | 2022-04-28 | 2024-01-01 | 美商辛瑟拉股份有限公司 | 三環parp1抑制劑及其用途 |
| WO2023227052A1 (zh) * | 2022-05-25 | 2023-11-30 | 西藏海思科制药有限公司 | 双环衍生物parp抑制剂及其用途 |
| WO2023232069A1 (zh) * | 2022-06-02 | 2023-12-07 | 成都苑东生物制药股份有限公司 | 一种氮杂喹啉酮类衍生物、其制备方法及用途 |
| WO2023242302A1 (en) * | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101822906B1 (ko) * | 2016-05-04 | 2018-01-29 | 동아대학교 산학협력단 | 저온 플라즈마 분사 장치를 이용한 암세포의 선택적 세포사멸 방법 및 이를 이용한 종양 치료 방법 |
| CR20210281A (es) * | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| WO2020150480A1 (en) * | 2019-01-17 | 2020-07-23 | Board Of Regents, The University Of Texas System | Methods for treatment of lung cancers |
| EP3999506A1 (en) * | 2019-07-19 | 2022-05-25 | Astrazeneca AB | Parp1 inhibitors |
| EP4072551A4 (en) * | 2019-12-11 | 2023-11-15 | Repare Therapeutics Inc. | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
-
2022
- 2022-06-16 EP EP22823742.6A patent/EP4355334A1/en active Pending
- 2022-06-16 KR KR1020247001149A patent/KR20240021884A/ko unknown
- 2022-06-16 WO PCT/CA2022/050970 patent/WO2022261777A1/en active Application Filing
- 2022-06-16 BR BR112023024942A patent/BR112023024942A2/pt unknown
- 2022-06-16 IL IL309388A patent/IL309388A/en unknown
- 2022-06-16 CA CA3222841A patent/CA3222841A1/en active Pending
- 2022-06-16 AU AU2022293208A patent/AU2022293208A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022261777A1 (en) | 2022-12-22 |
| KR20240021884A (ko) | 2024-02-19 |
| EP4355334A1 (en) | 2024-04-24 |
| CA3222841A1 (en) | 2022-12-22 |
| IL309388A (en) | 2024-02-01 |
| AU2022293208A1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023024942A2 (pt) | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer | |
| BR112022011426A2 (pt) | Uso de inibidores de atr em combinação com inibidores de parp | |
| BR112022002059A2 (pt) | Formas sólidas de um inibidor de hpk1 | |
| BR112016001457A2 (pt) | Inibidores de fatores de transcrição e usos dos mesmos | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112017009440A2 (pt) | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) | |
| BR112022014058A2 (pt) | Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms) | |
| BR112022021910A2 (pt) | Inibidores da proteína bcl-2 | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| BR112022001341A2 (pt) | Inibidores de enzima | |
| AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
| BR112017026201A2 (pt) | inibidores de mir-155 para o tratamento de linfoma cutâneo de células t (ctcl) | |
| BR112023024571A2 (pt) | Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 | |
| CR20230500A (es) | Métodos para inhibir ras | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| BR112018003291A2 (pt) | modulando a expressão da apolipoproteina (a) | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| BR112022001390A2 (pt) | Inibidores de enzima | |
| BR112023021913A2 (pt) | Tratamento de câncer com inibidor de raf | |
| BR112023022481A2 (pt) | Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica | |
| BR112022022305A2 (pt) | Combinação farmacêutica que compreende tno155 e nazartinibe | |
| BR112022007787A2 (pt) | Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer | |
| CO2023012342A2 (es) | Inhibidores de enzimas | |
| MX2021013271A (es) | Inhibidores de la via rank en combinacion con inhibidores de cdk. |